Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage
Autor: | Amirhossein Sahebkar, Fadel Lhaf, Thozhukat Sathyapalan, Habib Yaribeygi |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Blood Glucose Mitochondrial Diseases Glucagon-Like Peptides Apoptosis Deafness medicine.disease_cause 030226 pharmacology & pharmacy General Biochemistry Genetics and Molecular Biology Glucagon-Like Peptide-1 Receptor 03 medical and health sciences 0302 clinical medicine Glucagon-Like Peptide 1 Diabetes mellitus Neoplasms Medicine Humans Hypoglycemic Agents General Pharmacology Toxicology and Pharmaceutics Sodium-Glucose Transporter 2 Inhibitors Dipeptidyl peptidase-4 Glucagon-like peptide 1 receptor Dipeptidyl-Peptidase IV Inhibitors business.industry Cancer General Medicine medicine.disease 030104 developmental biology Diabetes Mellitus Type 2 Cancer cell Cancer research business Oxidative stress Intracellular |
Zdroj: | Life sciences. 231 |
ISSN: | 1879-0631 |
Popis: | Apoptosis is a complicated process that involves activation of a series of intracellular signaling. Tissue injuries from diabetes mellitus mostly occur as a consequence of higher rate of apoptosis process due to activation of a series of molecular mechanisms. Several classes of anti-hyperglycaemic agents have been developed which could potentially modulate the apoptotic process resulting in fewer tissue damages. Novel types of anti-hyperglycaemic medications such as sodium glucose cotransporters-2 inhibitors, glucagon like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors have shown to provide potent anti-hyperglycaemic effects, but their influences on diabetes-induced apoptotic injuries is largely unknown. Therefore, in the current study, we reviewed the published data about the possible effects of these anti-hyperglycaemic agents on apoptosis in diabetic milieu as well as in cancer cells. |
Databáze: | OpenAIRE |
Externí odkaz: |